Fortrea
Fortrea is recorded as a service provider in 397 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 397 trials · Latest update first
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of androgen receptor pathway inhibitor (ARPI) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of ARPI
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Open-label, Randomised, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A First-In-Human (FIH) phase I/II open-label, multicentre, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations.
Sponsor Pierre Fabre Medicament
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options
Sponsor Mundipharma Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Sponsor Johnson & Johnson Enterprise Innovation Inc.
- Start (EU)
- Latest update
- Estimated end
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Sponsor VarmX B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Sponsor Agios Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Participants were recruited at 26 investigative sites across 11 countries from 09 March 2022 to 09 April 2026.
- One participant was randomized in error, was not treated, and was excluded from the presented results.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 Years of Age) with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Fortrea?
The 2026-10-09 snapshot links Fortrea to 397 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Clinical monitoring, Regulatory services, Data management, among 125 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Fortrea?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Haematological Malignancies, Respiratory. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Fortrea conducted?
The linked trials record locations in 28 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Fortrea delivered services.
What can this page tell me about Fortrea's trial experience?
Browse 397 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 16 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 12 recorded name variants under Fortrea. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- FORTREA
- Fortrea
- Fortrea Belgium
- Fortrea Clinical Development Limited
- Fortrea Clinical Research Unit Limited
- Fortrea Development Limited
- Fortrea Development Limited Maidenhead Sucursala Bucuresti
- Fortrea Development Ltd. Branch Of Foreign Company
- Fortrea Development Ltd. Branch of Foreign Company
- Fortrea France S.A.R.L.
- Fortrea Germany GmbH
- Fortrea Inc.